Brendan Studebaker is a career biologist with experience building advanced therapeutic platforms and digital laboratory infrastructures for biotech organizations. He brings a rare combination of bench-level scientific expertise, operational leadership, and systems design. At Onnix, he applies this background to support the development and operational readiness of the company’s EDTA-based catheter lock/flush solution. 
 

Prior to joining the company, Brendan led cell line engineering and molecular biology programs at Link Cell Therapies, a CAR-T company developing solid-tumor therapies using GATE logic technology. He also contributed to gene-editing platform development at Graphite Bio and supported antibody discovery initiatives at Just–Evotec Biologics, working across vector design, molecular engineering, and the digital systems that enable modern R&D teams to operate efficiently and reliably. 
 

His background allows him to bridge technical execution with operational structure, ensuring that scientific programs are carried out with consistency, traceability, and scalability. 

At Onnix, Brendan supports operations, scientific coordination, and systems implementation as the company advances its EDTA-based catheter lock/flush solution toward clinical evaluation.